Research and Development Expense of IDEAYA Biosciences, Inc. from 31 Dec 2017 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
- Summary
-
IDEAYA Biosciences, Inc. quarterly and annual Research and Development Expense in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
- IDEAYA Biosciences, Inc. Research and Development Expense for the quarter ending 31 Dec 2025 was $86,599,000, a 38% decline year-over-year.
- IDEAYA Biosciences, Inc. Research and Development Expense for the twelve months ending 31 Dec 2025 was $314,704,000, a 6.8% increase year-over-year.
- IDEAYA Biosciences, Inc. annual Research and Development Expense for 2025 was $314,704,000, a 6.8% increase from 2024.
- IDEAYA Biosciences, Inc. annual Research and Development Expense for 2024 was $294,673,000, a 128% increase from 2023.
- IDEAYA Biosciences, Inc. annual Research and Development Expense for 2023 was $129,508,000, a 45% increase from 2022.
- Source SEC data
- View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)
IDEAYA Biosciences, Inc. Quarterly Research and Development Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $314,704,000 | $86,599,000 | -$53,584,000 | -38% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 17 Feb 2026 | 2025 | FY |
| Q3 2025 | $368,288,000 | $82,993,000 | +$25,841,000 | +45% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $342,447,000 | $74,226,000 | +$19,693,000 | +36% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $322,754,000 | $70,886,000 | +$28,081,000 | +66% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 06 May 2025 | 2025 | Q1 |
| Q4 2024 | $294,673,000 | $140,183,000 | +$101,413,000 | +262% | 01 Oct 2024 | 31 Dec 2024 | 10-K | 17 Feb 2026 | 2025 | FY |
| Q3 2024 | $193,260,000 | $57,152,000 | +$23,451,000 | +70% | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2024 | $169,809,000 | $54,533,000 | +$25,355,000 | +87% | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2024 | $144,454,000 | $42,805,000 | +$14,946,000 | +54% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 06 May 2025 | 2025 | Q1 |
| Q4 2023 | $129,508,000 | $38,770,000 | +$14,058,000 | +57% | 01 Oct 2023 | 31 Dec 2023 | 10-K | 17 Feb 2026 | 2025 | FY |
| Q3 2023 | $115,450,000 | $33,701,000 | +$11,329,000 | +51% | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 04 Nov 2024 | 2024 | Q3 |
| Q2 2023 | $104,121,000 | $29,178,000 | +$6,382,000 | +28% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 06 Aug 2024 | 2024 | Q2 |
| Q1 2023 | $97,739,000 | $27,859,000 | +$8,203,000 | +42% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 07 May 2024 | 2024 | Q1 |
| Q4 2022 | $89,536,000 | $24,712,000 | +$8,602,000 | +53% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 18 Feb 2025 | 2024 | FY |
| Q3 2022 | $80,934,000 | $22,372,000 | +$6,869,000 | +44% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 07 Nov 2023 | 2023 | Q3 |
| Q2 2022 | $74,065,000 | $22,796,000 | +$7,817,000 | +52% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 10 Aug 2023 | 2023 | Q2 |
| Q1 2022 | $66,248,000 | $19,656,000 | +$8,090,000 | +70% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 09 May 2023 | 2023 | Q1 |
| Q4 2021 | $58,158,000 | $16,110,000 | +$4,059,000 | +34% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 20 Feb 2024 | 2023 | FY |
| Q3 2021 | $54,099,000 | $15,503,000 | +$5,478,000 | +55% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 08 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $48,621,000 | $14,979,000 | +$6,383,000 | +74% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 15 Aug 2022 | 2022 | Q2 |
| Q1 2021 | $42,238,000 | $11,566,000 | +$2,540,000 | +28% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2020 | $39,698,000 | $12,051,000 | +$3,510,000 | +41% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 07 Mar 2023 | 2022 | FY |
| Q3 2020 | $36,188,000 | $10,025,000 | +$1,102,000 | +12% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 15 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $35,086,000 | $8,596,000 | -$263,000 | -3% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 10 Aug 2021 | 2021 | Q2 |
| Q1 2020 | $35,349,000 | $9,026,000 | +$1,030,000 | +13% | 01 Jan 2020 | 31 Mar 2020 | 10-Q | 10 May 2021 | 2021 | Q1 |
| Q4 2019 | $34,319,000 | $8,541,000 | 01 Oct 2019 | 31 Dec 2019 | 10-K | 18 Mar 2022 | 2021 | FY | ||
| Q3 2019 | $8,923,000 | -$3,615,000 | -29% | 01 Jul 2019 | 30 Sep 2019 | 10-Q | 12 Nov 2020 | 2020 | Q3 | |
| Q2 2019 | $8,859,000 | +$2,427,000 | +38% | 01 Apr 2019 | 30 Jun 2019 | 10-Q | 12 Aug 2020 | 2020 | Q2 | |
| Q1 2019 | $7,996,000 | 01 Jan 2019 | 31 Mar 2019 | 10-Q | 12 May 2020 | 2020 | Q1 | |||
| Q3 2018 | $12,538,000 | 01 Jul 2018 | 30 Sep 2018 | 10-Q | 13 Nov 2019 | 2019 | Q3 | |||
| Q2 2018 | $6,432,000 | 01 Apr 2018 | 30 Jun 2018 | 10-Q | 12 Aug 2019 | 2019 | Q2 |
IDEAYA Biosciences, Inc. Annual Research and Development Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $314,704,000 | +$20,031,000 | +6.8% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 17 Feb 2026 | 2025 | FY |
| 2024 | $294,673,000 | +$165,165,000 | +128% | 01 Jan 2024 | 31 Dec 2024 | 10-K | 17 Feb 2026 | 2025 | FY |
| 2023 | $129,508,000 | +$39,972,000 | +45% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 17 Feb 2026 | 2025 | FY |
| 2022 | $89,536,000 | +$31,378,000 | +54% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 18 Feb 2025 | 2024 | FY |
| 2021 | $58,158,000 | +$18,460,000 | +47% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 20 Feb 2024 | 2023 | FY |
| 2020 | $39,698,000 | +$5,379,000 | +16% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 07 Mar 2023 | 2022 | FY |
| 2019 | $34,319,000 | +$2,570,000 | +8.1% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 18 Mar 2022 | 2021 | FY |
| 2018 | $31,749,000 | +$19,365,000 | +156% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 23 Mar 2021 | 2020 | FY |
| 2017 | $12,384,000 | 01 Jan 2017 | 31 Dec 2017 | 10-K | 24 Mar 2020 | 2019 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.